drugset / Trial / NCT00210379
Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective assess the clinical activity of combination doxorubicin-containing chemotherapy plus monoclonal antibody anti-CD20 (Rituximab) plus intrathecal prophylactic chemotherapy and loco-regional radiotherapy in primary localised testicular DLCL and to assess the toxicity of this therapeutic strategy
Timeline
- Start
- 2000-11
- Primary completion
- 2004-11
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | — | Intrathecal |
| Subject | Rituximab | Monoclonal antibody | — | — |